Cara Therapeutics (NASDAQ:CARA) shares traded 11.38% up during most recent session to reach at the closing price of $13.7. The stock exchanged hands 1.92 Million shares versus average trading capacity of 1.06 Million shares, yielding a market cap of $443.06 Million. Wall Street analysts covering the stock are projecting that the stock will reach $24.29 within the next 52-weeks. The mean target projections are based on 7 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Cara Therapeutics (NASDAQ:CARA) high price target of $30 and with a conservative view have low price target of $17.
Janney Capital “Upgrades” Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on 2/12/18 to Buy with price target of $0.
Additionally on 1/19/18 Seaport Global “Initiates Coverage On” Cara Therapeutics (NASDAQ:CARA) to Buy setting price target at $27 and on 6/30/17 Janney Capital “Downgrades” the stock to Neutral at $21. Furthermore on 10/13/16 H.C. Wainwright “Initiates Coverage On” the stock to Buy.
On the other hand the company has Relative Strength Index (RSI 14) of 52.63 along with Average True Range (ATR 14) of 0.93, Consequently Cara Therapeutics (NASDAQ:CARA)’s weekly and monthly volatility is 7.68%, 6.89% respectively. The company’s beta value is at 2.84.
In terms of Buy, Sell or Hold recommendations, Cara Therapeutics (NASDAQ:CARA) has analysts’ mean recommendation of 1.9. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Cara Therapeutics (NASDAQ:CARA)’s minimum EPS for the current quarter is at $-0.46 and can go high up to $-0.32. The consensus mean EPS for the current quarter is at $-0.4 derived from a total of 7 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.81 earnings per share for the same quarter during last year.
Previously Cara Therapeutics (NASDAQ:CARA) reported $-0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.34 by $-0.04. The company posted an earnings surprise of -11.8%.
Currently Cara Therapeutics (NASDAQ:CARA)’s shares owned by insiders are 3.7%, whereas shares owned by institutional owners are 56.5%. However the six-month change in the insider ownership was recorded -3.51%, as well as three-month change in the institutional ownership was recorded -7.12%.
Cara Therapeutics (NASDAQ:CARA) 52-week high price stands at $28.50 and low price stands at $11.11, its price distance from 52-week high is -51.93% while its distance from 52-week low price is 23.31%. The stock hit its 52-week high on 06/27/17, and 52-week low on 11/03/17.
Cara Therapeutics (NASDAQ:CARA)’s trailing twelve month revenues are $900000, whereas its price to sales ratio for the same period is 492.29. Its book value per share for the most recent quarter is $3.04 while its price to book ratio for the same period is 4.51, as for as the company’s cash per share for the most recent quarter is $3.18, however its price to cash per share ratio for the same period is 4.3. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.